TIGERTRIEVER™ 13 is the first device shown to meet safety and effectiveness endpoints for restoring blood flow in smaller but critical areas of the brain, accounting for almost 50% of all ischemic...
The FDA clearances expand Vesalio’s thrombectomy portfolio to support its growth strategy in the rapidly expanding multi-billion-dollar global thrombectomy market.Plano, Texas – November 18, 2025
Basel, Switzerland – June 2025 – The University Hospital Basel, under the direction of Prof. Dr. Marios‑Nikos Psychogios, has officially launched the ICARUS study (“IntraCranial Atherosclerosi...